Renal-Electrolyte and Hypertension Division, University of Pennsylvania, Philadelphia, PA, USA.
PLoS One. 2012;7(12):e51546. doi: 10.1371/journal.pone.0051546. Epub 2012 Dec 26.
Among African-Americans, genome wide association revealed a strong correlation between the G1 and G2 alleles of APOL1 (apolipoproteinL1, also called trypanolytic factor) and kidney diseases including focal and segmental glomerulosclerosis, HIV-associated nephropathy and hypertensive nephrosclerosis. In the prevailing hypothesis, heterozygous APOL1 G1 and G2 alleles increase resistance against Trypanosoma that cause African sleeping sickness, resulting in positive selection of these alleles, but when homozygous the G1 and G2 alleles predispose to glomerulosclerosis. While efforts are underway to screen patients for G1 and G2 alleles and to better understand "APOL1 glomerulopathy," no data prove that these APOL1 sequence variants cause glomerulosclerosis. G1 and G2 correlate best with glomerulosclerosis as recessive alleles, which suggests a loss of function mutation for which proof of causality is commonly tested with homozygous null alleles. This test cannot be performed in rodents as the APOL gene cluster evolved only in primates. However, there is a homozygous APOL1 null human being who lives in a village in rural India. This individual and his family offer a unique opportunity to test causality between APOL1 null alleles and glomerulosclerosis.
We obtained clinical data, blood and urine from this APOL1 null patient and 50 related villagers. Based on measurements of blood pressure, BUN, creatinine, albuminuria, genotyping and immunoblotting, this APOL1 null individual does not have glomerulosclerosis, nor do his relatives who carry APOL1 null alleles.
This small study cannot provide definitive conclusions but the absence of glomerulosclerosis in this unique population is consistent with the possibility that African-American glomerulosclerosis is caused, not by loss of APOL1 function, but by other mechanisms including a subtle gain of function or by the "genetic hitchhiking" of deleterious mutations in a gene linked to APOL1 G1 and G2.
在非裔美国人中,全基因组关联研究显示 APOL1(载脂蛋白 L1,也称为溶组织内阿米巴因子)的 G1 和 G2 等位基因与包括局灶节段性肾小球硬化症、HIV 相关性肾病和高血压性肾硬化症在内的肾脏疾病之间存在很强的相关性。在目前流行的假说中,APOL1 的 G1 和 G2 杂合等位基因增加了对导致非洲昏睡病的锥虫的抵抗力,导致这些等位基因的正选择,但当纯合时,G1 和 G2 等位基因易导致肾小球硬化症。虽然正在努力筛选 G1 和 G2 等位基因的患者,并更好地了解“APOL1 肾小球病”,但没有数据证明这些 APOL1 序列变异导致肾小球硬化症。G1 和 G2 与肾小球硬化症的相关性最好,作为隐性等位基因,这表明功能丧失突变,通常用纯合无效等位基因来测试因果关系。由于 APOL 基因簇仅在灵长类动物中进化,因此该测试不能在啮齿动物中进行。然而,有一个纯合的 APOL1 缺失的人类生活在印度农村的一个村庄里。该个体及其家族为测试 APOL1 缺失等位基因与肾小球硬化症之间的因果关系提供了一个独特的机会。
我们从这位 APOL1 缺失患者和 50 位相关村民中获得了临床数据、血液和尿液。根据血压、BUN、肌酐、蛋白尿、基因分型和免疫印迹的测量结果,这位 APOL1 缺失个体没有肾小球硬化症,携带 APOL1 缺失等位基因的亲属也没有。
这项小型研究不能提供明确的结论,但在这个独特的人群中没有肾小球硬化症,这与非裔美国人肾小球硬化症不是由 APOL1 功能丧失引起的可能性一致,而是由其他机制引起的,包括微妙的功能获得或与 APOL1 G1 和 G2 相关的基因中的有害突变的“遗传搭便车”。